<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770000</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530+Romidepsin-1805</org_study_id>
    <nct_id>NCT03770000</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma</brief_title>
  <official_title>An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of&#xD;
      Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">May 14, 2021</completion_date>
  <primary_completion_date type="Actual">May 14, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in Patients with T cell lymphoma</measure>
    <time_frame>28 days</time_frame>
    <description>The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 28-day cycle of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) with Tenalisib and Romidepsin combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>No. of patients with partial and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) with Tenalisib and Romidepsin combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>The time period from the response achieved in patient until the disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>8 days</time_frame>
    <description>Assessment of Cmax in subjects treated with Tenalisib and Romidepsin combination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tenalisib+Romidepsin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib</intervention_name>
    <description>Tenalisib, BID orally daily</description>
    <arm_group_label>Tenalisib+Romidepsin</arm_group_label>
    <other_name>RP6530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Romidepsin IV</description>
    <arm_group_label>Tenalisib+Romidepsin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically confirmed T-cell lymphomas at the enrolling institution.&#xD;
&#xD;
          2. Disease status as defined as relapsed or progressed patients who have received at&#xD;
             least one systemic therapy.&#xD;
&#xD;
          3. The patients should have received NOT more than three prior systemic combination&#xD;
             chemotherapies&#xD;
&#xD;
          4. PTCL patients must have measurable disease defined as at least one bidimensional&#xD;
             measurable lesion with minimum measurement of &gt; 1.5 cm in the longest diameter.&#xD;
&#xD;
          5. Must have ECOG performance status ≤ 2&#xD;
&#xD;
          6. Adequate bone marrow, liver and renal function in line with below mentioned laboratory&#xD;
             requirements.&#xD;
&#xD;
               1. Hemoglobin ≥8.0 g/dL&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥1,000/µL&#xD;
&#xD;
               3. Platelet count ≥75,000/μL&#xD;
&#xD;
               4. Total bilirubin ≤1.5 times the ULN (or ≤3 x ULN, if patient has Gilbert syndrome)&#xD;
&#xD;
               5. AST (SGOT) and ALT (SGPT) ≤ 3 x ULN; ≤ 5 ULN in case of liver involvement&#xD;
&#xD;
               6. Calculated creatinine clearance (CrCl) &gt; 50 ml/min by Cockcroft-Gault formula&#xD;
&#xD;
          7. Use of an effective means of contraception for women of childbearing potential and men&#xD;
             with partners of childbearing potential.&#xD;
&#xD;
          8. Provide written informed consent prior to any study-specific screening procedures.&#xD;
&#xD;
          9. Willingness and capability to comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient receiving anticancer therapy including any investigational therapy ≤3 weeks or&#xD;
             5 half-lives (whichever is shorter) prior to C1D1.&#xD;
&#xD;
          2. Patient who discontinued prior therapy with PI3K inhibitors or HDAC inhibitors due to&#xD;
             drug toxicity.&#xD;
&#xD;
          3. PTCL patients with Allo-SCT on active GVHD or immunosuppression therapy within 3&#xD;
             months prior to C1D1. CTCL patients with the history of Allo-SCT will be excluded.&#xD;
&#xD;
          4. Patient with medical conditions requiring the use of systemic immunosuppressive&#xD;
             medications (&gt; 20 mg/day of prednisone or equivalent).&#xD;
&#xD;
          5. Severe bacterial, viral or mycotic infection requiring systemic treatment.&#xD;
&#xD;
          6. Known seropositive requiring anti-viral therapy for human immunodeficiency virus (HIV)&#xD;
             infection.&#xD;
&#xD;
          7. Known seropositive requiring anti-viral therapy for hepatitis B virus (HBV) infection&#xD;
             OR evidence of active hepatitis B infection as defined by detectable viral load if the&#xD;
             antibody tests are positive..&#xD;
&#xD;
          8. Known seropositive requiring anti-viral therapy for hepatitis c virus (HCV) infection&#xD;
             OR patients with positive hepatitis C virus Ab.&#xD;
&#xD;
          9. Subjects with active EBV unrelated to underlying lymphoma (positive serology for anti-&#xD;
             EBV VCA IgM antibody and negative for anti-EBV EBNA IgG antibody, or clinical&#xD;
             manifestations and positive EBV PCR consistent with active EBV infection.&#xD;
&#xD;
         10. Subject with active CMV (positive serology for anti-CMV IgM antibody and negative for&#xD;
             anti-CMV IgG antibody and positive CMV PCR with clinical manifestations consistent&#xD;
             with active CMV infection) and requiring therapy.&#xD;
&#xD;
         11. Uncontrolled or significant cardiovascular disease including, but not limited to:&#xD;
&#xD;
               -  Congenital long QT syndrome.&#xD;
&#xD;
               -  QTcF interval &gt; 450 msec&#xD;
&#xD;
               -  Myocardial infarction or stroke/TIA within the past 6 months&#xD;
&#xD;
               -  Uncontrolled angina within the past 3 months&#xD;
&#xD;
               -  Significant ECG abnormalities including 2nd degree atrio- ventricular (AV) block&#xD;
                  (AV) block type II, 3rd degree AV block.&#xD;
&#xD;
               -  History of clinically significant arrhythmias (such as ventricular tachycardia,&#xD;
                  ventricular fibrillation or torsades de pointes),&#xD;
&#xD;
               -  History of other clinically significant heart disease (ie, cardiomyopathy,&#xD;
                  congestive heart failure with NYHA functional classification III-IV,&#xD;
                  pericarditis, significant pericardial effusion)&#xD;
&#xD;
               -  Requirement for daily supplemental oxygen therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Hellen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami-Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, St Matthews Campus</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center, Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center,</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T cell Lymphoma</keyword>
  <keyword>RP6530</keyword>
  <keyword>Tenalisib</keyword>
  <keyword>Romidepsin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
    <mesh_term>Tenalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

